Biotech Overhyping Obesity Drug Hurt Investors, Suit Says
Current and former executives of drugmaker Skye Bioscience Inc. breached their fiduciary duties by overstating an obesity drug's clinical prospects and precipitating a trading price decline when the company revealed disappointing...To view the full article, register now.
Already a subscriber? Click here to view full article